The global cancer profiling market is expected to yield significant gains across 2021, as preference for precision-based medicine and high quality oncology care acquires increasing traction. With global cancer burden slated to proliferate, patients and medical practitioners alike are scrambling to offer highly efficacious and long-lasting cancer diagnostics, prompting the entry of numerous service providers.
Key solution providers are effectively leveraging smart technology, nanomedicine, and automation to accelerate diagnostic processes. Reduction in testing timeframes to provide accurate results has helped patients seek timely treatment to mitigate their cancers. The report by Fact.MR provides a taxonomy elaborating on key market segments. It also outlines visionary insights on the dynamics of the market, including the drivers, restraints, opportunities, trends, and pricing analysis, along with key success factors. Market trends have been tracked in 20+ high-growth countries.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=358
As per the research report compiled by Fact.MR, the global cancer profiling market is expected to witness strong growth, registering 17.7% CAGR during the forecast period 2017-2026. By the end of 2026, the global cancer profiling market is estimated to reach US$ 122,129.6 million revenue. Increasing incidences of new cases of cancer are resulting in the rising use of cancer profiling. As per National Cancer Institute, new cancer cases are likely to reach 22 million within next two years. Moreover, increasing adoption of precision medicine treatment is also driving the demand for cancer profiling. Below are the few insights on how the global cancer profiling market will perform in the coming years.
Forecast Highlights on Global Cancer Profiling Market
1- North America is expected to remain dominant in the global cancer profiling market during the forecast period 2017-2026. Changing lifestyle with increasing consumption of alcohol, smoking is leading to the increasing number of people suffering from cancer. Moreover, increasing investment in research and development activities are driving the demand for cancer profiling in the region.
2- Asia Pacific Excluding Japan (APEJ) and Europe are also witnessing significant growth in the cancer profiling. Increasing incidence of lung cancer and prostate cancer in central, eastern, and southern Europe is driving the demand for cancer profiling. Meanwhile, breast cancer is the most diagnosed cancer among women in China and India.
3- Next-generation sequencing is expected to be the highly-preferred technique in cancer profiling market. By the end of 2026, next-generation sequencing is estimated to reach 62,000 million revenue.
4- Pharmaceutical and biotech companies are expected to be the largest users of cancer profiling. Pharmaceutical and biotech companies are estimated to surpass US$ 52,400 million revenue by the end of 2026.
5- Diagnosis is expected to witness significant growth in the global cancer profiling market. By the end of 2026, diagnosis is estimated to surpass US$ 40,000 million in terms of revenue.
For customized report: https://www.factmr.com/connectus/sample?flag=RC&rep_id=358
The report has also profiled leading players in the global market for cancer profiling, which will remain active through 2026. These include companies such as Roche Holdings, Caris Life Sciences, GenScript, Illumina, Inc. (U.S.), Proteome Sciences PLC, BioTheranostics, NeoGenomics Laboratories, RiboMed Biotechnologies Inc., Genomic Health Inc., Oxford Gene Technology Ltd., and Agendia.
Buy Now : https://www.factmr.com/checkout/358/S
Country-wise Analysis
How Lucrative is the U.S. Cancer Profiling Market?
The United States is expected to garner significant share in the cancer profiling landscape. A study conducted by the American Cancer Society projects a substantial increase in the incidence of numerous cancers across the country in 2021. It estimates that, over 1.8 million people are expected to suffer from some or the other malignancy, with over 600 thousand deaths. Therefore, government initiatives have been undertaken to contain the spread of this debilitating disease. These include launching awareness campaigns and promoting highly advanced cancer profiling and detection research.
The National Cancer Institute has been playing a pivotal in advancing sophisticated cancer research studies and initiatives, including on cancer biology, cancer genomics, and cancer prevention. At present, the agency is working on determining the efficacy of patient derived xenograft (PDX) mice-based clinical trials. These mice largely retain the genetics of human tumors from which they were initially created. This is expected to reassure clinicians about the validity of novel cancer treatment and detection studies and approaches.
For more insights: https://www.biospace.com/article/autologous-fat-grafting-is-emerging-as-a-safer-substitute-to-breast-enlargement-procedures-fact-mr/
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
